Skip to main content

Advertisement

Table 4 The REMARK profile

From: The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma

(a) Patients, treatment and variables
Study and marker Remarks
 Prognostic factor M = the interval between IC and RT (days from the end of the last cycle of IC to the initiation of RT); categorized into 5 groups (≤ 10, 11–20, 21–30, 31–40 and ≥ 41), or 2 groups (≤ 30 and > 30)
 Further variables v1 = age, v2 = gender, v3 = CCI score, v4 = T category, v5 = N category, v6 = lnDNA, v7 = WHO pathology type, v8 = IC cycles, v9 = concurrent chemotherapy
Patients Number Remarks
 Assessed for eligibility 2191 Disease: newly diagnosed, biopsy-proven, non-metastatic NPC
Patient source: 2009.11–2012.10, Sun Yat-sen University Cancer Center
 Excluded 1523 Exclusion criteria: not receiving IC before RT; without pretreatment plasma EBV DNA
 Included 668 Treatment: all received IC and IMRT with or without concurrent chemotherapy
 Primary outcome events
  OS 108 OS: from the initiation of therapy to death from any cause
 Secondary outcomes events
  DFS 158 DFS: from the initiation of therapy to failure or death from any cause, whichever occurred first
  DMFS 89 DMFS: from the initiation of therapy to first distant failure
  LRFS 70 LRFS: from the initiation of therapy to first locoregional failure
(b) Statistical analyses of survival outcomes
Analysis Variables considered Results/remarks
 A1: Univariate for OS M Fig. 1; the interval was categorized into 5 groups
 A2: Univariate for OS, DFS, DMFS, LRFS M, v1-v9 Fig. 2, Table 2; the interval was categorized into 2 groups
 A3: Multivariate for OS, DFS, DMFS, LRFS M, v1-v9 Table 3; variables in final model: OS (M, v1, v3, v4, v5, v6), DFS (M, v1, v3, v5, v6), DMFS (M, v3, v5, v6), LRFS (M, v5, v6, v7)
 A4: Interval in v5 subgroups for OS, DFS, DMFS M, v5 Additional file 1: Figures S3 and S6
 A5: Interval in v8 subgroups for OS, DFS, DMFS M, v8 Additional file 1: Figures S4 and S6
 A6: Interval in v9 subgroups for OS, DFS, DMFS M, v9 Additional file 1: Figures S5 and S6
  1. Abbreviations: IC Induction chemotherapy, RT Radiotherapy, CCI Charlson comorbidity index, NPC Nasopharyngeal carcinoma, EBV Epstein-Barr virus, IMRT Intensity modulated radiotherapy, OS Overall survival, DFS Disease-free survival, DMFS Distant metastasis-free survival, LRFS Locoregional recurrence-free survival